300006.SHE – Chongqing Lummy Pharmaceutical

Last Day

Drug Manufacturers – General

• Trailing PE:
• Forward PE:
• Price Sales TTM:
• Price Book MRQ:
• Enterprise Value:
• Enterprise Value Revenue:
• Enterprise Value Ebitda:
• Beta:

• Shares Outstanding:
• Market Capitalization:
• Market Capitalization Mln:
• EBITDA:
• PE Ratio:
• PEG Ratio:
• Wall Street Target Price:
• Book Value:
• Dividend Share:
• Dividend Yield:
• Earnings Share:
• EPS Estimate Current Year:
• EPS Estimate Next Year:
• EPS Estimate Next Quarter:
• EPS Estimate Current Quarter:
• Most Recent Quarter:
• Profit Margin:
• Operating Margin TTM:
• Return On Assets TTM:
• Return On Equity TTM:
• Revenue TTM:
• Revenue Per Share TTM:
• Quarterly Revenue Growth YOY:
• Gross Profit TTM:
• Diluted Eps TTM:
• Quarterly Earnings Growth YOY:

• Type:
• Name:
• Exchange:
• Currency Code:
• Currency Name:
• Currency Symbol:
• Country Name:
• Fiscal Year End:
• IPO Date:
• International Domestic:
• Sector:
• Industry:
• Address:
• Country:
• Listings:
• Web URL:
• Full Time Employees:
• Updated At:
• Gic Sector:
• Gic Group:
• Gic Industry:
• Gic SubIndustry:

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Chongqing, China. Address: Building B, Huangshan Avenue, Chongqing, China, 401121

The data, information and layout displayed above cannot be used for commercial purpose. We do not accept any liability for reliance of the information above. We can provide description of source data regarding our industry research and valuation research to our clients upon request.